Characterization of T lymphocytes mediatingin vivo protection against RSV-induced murine sarcomas (original) (raw)
1983, International Journal of Cancer
ferent mouse strains share a common tumor-assuciated transplantation antigen, whose expression is controlled both by the viral transforming SK gene and by cellular gene(s) . The mechanism(s) responsible for the in vivo protective immune response against two RSV-induced sarcomas has now been investigated. In the "Winn assay" the growth of both tumors was specifically prevented or significantly reduced by the simultaneous administration of lymphocytes isolated from immunized donors. The effector cells were radiosensitive (2,500 rad), Lyt-I +, Lyt-2,3+ Thy. I + cells. Better protection was afforded by transfer of immune spleen cells from mice pretreated with cyclophosphamide, which is known to abrogate T-cell suppressor activity. In a 5-day mixed lymphocyte/tumor cell culture specific anti-RSV-induced sarcoma cytotoxic activity was barely detected, while a good production of interferon-gamma (IFN-y) was observed. The cells involved showed the same functional and surface phenotype as displayed by the effectors of the "Winn" assay. It is concluded that in the immune rejection of RSVinduced sarcomas. Lyt-I+, Lyt-2,3+ T cells, rather than cytotoxic T lymphocytes, and lymphokines such as IFN-7 are involved.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
International Journal of Cancer, 1974
BALBIc mice injected with Moloney sarcoma virus (M S V) developed local tumors at the site of inoculation which spontaneously regressed within 20-25 days after injection. Lymphocytes and sera from long-term regressor animals were examined for their specific activities in vitro against Moloney leulcemia virus (M L V) determined antigen (s). Specific activity against the M L V-positive target cells by the lymphocytes from these animals was found to be dependent on the presence of B lymphocytes. In order to investigate some of the possible mechanisms of action of the immune B cells, sera, which were characterized by complement-dependent cytotoxicity, immunofluorescence and virus neutralization, were tested for their ability to stimulate normal syngeneic lymphocytes to be active against the target cells. These antisera placed on the target cells were found to stimulate normal unfractionated or T deprived cells to reduce the targetcell numbers. This effect was not found with normal Tlymphocytes. Time-course kinetics of this antibody-dependent cell-mediated activity in vitro were defined. Adult BALB/c mice injected with Moloney Sarcoma Virus (MSV) develop tumors at thz site of injection with a high incidence of spontaneous regression (Fefer et al., 1967, 1968). Lymphocytes from such animals are active in vitro against target cells possessing the Moloney Leukemia Virus-associated cell-surface antigen(s). This lymphocyte activity has been evalusted by 51Cr release from labelled target cells (Leclerc et al., 1972, 1973) and by reduction of target cell numbers in microcytotoxicity tests (Lamon et al., 1972a,b, 1973a,b). The subpopulations of lymphocytes which are active in this system. have recently begun to be defined (
Journal of Experimental Medicine, 1977
As background for a serological definition of the unique antigens of chemically induced sarcomas, we have typed a series of fibroblast and sarcoma cell lines of BALB/c and C57BL/6 origin by cytoxicity and absorption tests for murine leukemia virus (MuLV)-related cell surface antigens and known alloantigens. 7 of the 17 cultured lines expressed the range of cell surface antigens associated with MuLV (GIX, GCSA, gp70, p30), and this was invariably associated with MuLV production. In nonproducer lines of C57BL/6 (but not BALB/c) origin, a MuLV-gp70-like molecule was found on the surface of fibroblasts and sarcoma cells. The alloantigenic phenotype of these MuLV+ and MuLV- cell lines was H-2D+, H-2K+, Thy-1.2+ or -, PC.1+ or -, Lyt-1.2-, Lyt-2.2-, Ia.7-, and TL.2-. A unique antigen was defined on the BALB/c ascites sarcoma Meth A with antisera prepared in BALB/c or (BALB/c X C57BL/6)F1 mice. Tissue culture lines derived from this tumor were MuLV-, which facilitated serological study of ...
Cancer research, 1973
Hamsters were immunized against reticulum cell sarcoma transplants by using tumor-associated antigens (TAA) ex tracted by sonication from the tumor cells. After tumor cell challenge, more than one-half of the immunized animals (51.37%) completely rejected the tumor whereas 35.73% exhibited a longer latency period than did unimmunized animals. All the immunized animals exhibited cell-mediated immunity against TAA as measured by footpad test and microcytotoxicity test. In all the animals in which a tumor developed at any time after the tumor cells challenge, blocking antibodies did develop in their serum at the time of appearance of the tumor. The immune status of hamsters receiving transplants was also studied to define whether any immune response de veloped after transplantation of syngeneic tumor cells. In Group 1, which received a low inoculum, tumors developed as fast as in Group 3, which received high inoculum. Several animals in Group 2, which received an intermediate inoculum, completely rejected the tumor, and in many the tumor developed after a long latent period. All the tests showed an absence of immune response in Group 1, as if the few cells could not elicit an immune response. In Group 2, the animals rejecting the tumor did not present any blocking activity in their sera; therefore, the cell-mediated immune response could be effective in the rejection of the tumor. Animals showing a delayed tumor growth exhibited blocking activity in their sera. In all the animals in Group 3,a cell-mediated immune response developed comparable with the one observed in immunized animals, and also, a strong blocking activity in their sera. The time of blocking activity appeared closely related to the appearance of the tumor. Immunization with TAA or suitable amount of tumor transplant appeared capable of eliciting a beneficial cell-mediated response except when blocking anti bodies were also present.
Journal of immunology (Baltimore, Md. : 1950), 1979
BN rats immunized subcutaneously with a viral induced tumor (MST) or with a chemical-induced fibrosarcoma (BC5) were donors of immune spleen cells. Samples of immune spleen cells were tested in vitro against MST and BC5 in a 51Cr release assay before culturing and after 7 days of culture with mitomycin C-treated MST and/or BC5 tumor cells (MSTMit, BC5Mit). These spleen cells were infused in vivo i.v. into x-rayed (400 R) and nonirradiated BN recipients that bore a vascularized and progressive (1 to 1.5 cm in diameter) subcutaneous MST or BC5. Spleen cells from untreated BN donor rats were also tested in vitro and in vivo as controls. Established MST were specifically eliminated by spleen cells immune to MST after culture with MSTMit, but not by spleen cells immune to MST without further culture nor by cultured or uncultured BC5 immune spleen cells and control spleen cells. Also, the growth of BC5 was not affected by MST immune spleen cells cultured for 7 days with MST and/or BC5. El...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.